Cargando…

Half-life time prediction of developing first-line antiretroviral treatment failure and its risk factors among TB and HIV co-infected children in Northwest Ethiopia; multi setting historical follow-up study

BACKGROUND: Even though treatment failure is higher among TB and HIV infected children in a resource-limited setting, there is no prior evidence in general and in the study area in particular. Hence, this study was aimed at determining the half-life time prediction of developing first-line antiretro...

Descripción completa

Detalles Bibliográficos
Autores principales: Chanie, Ermias Sisay, Muche, Achenef Asmamaw, Gobeza, Mengistu Berhanu, Alemu, Eshetie Molla, Addis, Wondimnew Desalegn, Azanaw, Melkalem Mamuye, Gebremariam, Alemayehu Digssie, Tesfa, Desalegn, Engidaw, Melaku Tadege, Atikilit, Getaneh, AbebawTiruneh, Sofonyas, Arage, Getachew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8892785/
https://www.ncbi.nlm.nih.gov/pubmed/35241036
http://dx.doi.org/10.1186/s12887-022-03177-6
_version_ 1784662258374148096
author Chanie, Ermias Sisay
Muche, Achenef Asmamaw
Gobeza, Mengistu Berhanu
Alemu, Eshetie Molla
Addis, Wondimnew Desalegn
Azanaw, Melkalem Mamuye
Gebremariam, Alemayehu Digssie
Tesfa, Desalegn
Engidaw, Melaku Tadege
Atikilit, Getaneh
AbebawTiruneh, Sofonyas
Arage, Getachew
author_facet Chanie, Ermias Sisay
Muche, Achenef Asmamaw
Gobeza, Mengistu Berhanu
Alemu, Eshetie Molla
Addis, Wondimnew Desalegn
Azanaw, Melkalem Mamuye
Gebremariam, Alemayehu Digssie
Tesfa, Desalegn
Engidaw, Melaku Tadege
Atikilit, Getaneh
AbebawTiruneh, Sofonyas
Arage, Getachew
author_sort Chanie, Ermias Sisay
collection PubMed
description BACKGROUND: Even though treatment failure is higher among TB and HIV infected children in a resource-limited setting, there is no prior evidence in general and in the study area in particular. Hence, this study was aimed at determining the half-life time prediction of developing first-line antiretroviral treatment failure and its risk factors among TB and HIV co-infected children. METHODS: A historical follow-up study was employed among 239 TB and HIV co-infected children from January 2010-December 2020. The data was entered into Epi data version 4.2.2 and exported to STATA 14.0 Software for analysis. The Kaplan-Meier plot was used to estimate the half-life time to develop treatment failure. The required assumption was fulfilled for each predictor variable. Additionally, those variables having a p-value ≤0.25 in the bivariable analysis were fitted into a multivariable Cox-proportional hazards regression model. P-value, < 0.05 was used to declare a significant association. RESULTS: A total of 239 TB and HIV co-infected children were involved in this study. The overall half-life time to develop first treatment failure was found to be 101 months, with a total of 1027.8 years’ follow-up period. The incidence rate and proportion of developing first-line treatment failure were 5.5 per 100 PPY (Person-Year) [CI (confidence interval): 3.7, 6.9] 100 PPY and 23.8% (CI; 18.8, 29.7) respectively. Factors such as hemoglobin 10 mg/dl [AHR (Adjusted Hazard Ratio): 3.2 (95% CI: 1.30, 7.73), severe acute malnutrition [AHR: 3.8 (95% CI: 1.51, 79.65), World Health Organization stage IV [AHR: 2.4 (95% CI: 1.15, 4.93)], and cotrimoxazole prophylaxis non user [AHR: 2.3 (95% CI: 1.14, 4.47)] were found to be a risk factor to develop treatment failure. CONCLUSION: In this study, the half-life time to develop first-line treatment failure was found to be very low. In addition, the incidence was found to be very high. The presence of hemoglobin 10 mg/dl, severe acute malnutrition, World Health Organization stage, and non-use of cotrimoxazole prophylaxis were discovered to be risk factors for treatment failure. Further prospective cohort and qualitative studies should be conducted to improve the quality of care in paediatric ART clinics to reduce the incidence or burden of first line treatment failure among TB and HIV co-infected children.
format Online
Article
Text
id pubmed-8892785
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-88927852022-03-10 Half-life time prediction of developing first-line antiretroviral treatment failure and its risk factors among TB and HIV co-infected children in Northwest Ethiopia; multi setting historical follow-up study Chanie, Ermias Sisay Muche, Achenef Asmamaw Gobeza, Mengistu Berhanu Alemu, Eshetie Molla Addis, Wondimnew Desalegn Azanaw, Melkalem Mamuye Gebremariam, Alemayehu Digssie Tesfa, Desalegn Engidaw, Melaku Tadege Atikilit, Getaneh AbebawTiruneh, Sofonyas Arage, Getachew BMC Pediatr Research BACKGROUND: Even though treatment failure is higher among TB and HIV infected children in a resource-limited setting, there is no prior evidence in general and in the study area in particular. Hence, this study was aimed at determining the half-life time prediction of developing first-line antiretroviral treatment failure and its risk factors among TB and HIV co-infected children. METHODS: A historical follow-up study was employed among 239 TB and HIV co-infected children from January 2010-December 2020. The data was entered into Epi data version 4.2.2 and exported to STATA 14.0 Software for analysis. The Kaplan-Meier plot was used to estimate the half-life time to develop treatment failure. The required assumption was fulfilled for each predictor variable. Additionally, those variables having a p-value ≤0.25 in the bivariable analysis were fitted into a multivariable Cox-proportional hazards regression model. P-value, < 0.05 was used to declare a significant association. RESULTS: A total of 239 TB and HIV co-infected children were involved in this study. The overall half-life time to develop first treatment failure was found to be 101 months, with a total of 1027.8 years’ follow-up period. The incidence rate and proportion of developing first-line treatment failure were 5.5 per 100 PPY (Person-Year) [CI (confidence interval): 3.7, 6.9] 100 PPY and 23.8% (CI; 18.8, 29.7) respectively. Factors such as hemoglobin 10 mg/dl [AHR (Adjusted Hazard Ratio): 3.2 (95% CI: 1.30, 7.73), severe acute malnutrition [AHR: 3.8 (95% CI: 1.51, 79.65), World Health Organization stage IV [AHR: 2.4 (95% CI: 1.15, 4.93)], and cotrimoxazole prophylaxis non user [AHR: 2.3 (95% CI: 1.14, 4.47)] were found to be a risk factor to develop treatment failure. CONCLUSION: In this study, the half-life time to develop first-line treatment failure was found to be very low. In addition, the incidence was found to be very high. The presence of hemoglobin 10 mg/dl, severe acute malnutrition, World Health Organization stage, and non-use of cotrimoxazole prophylaxis were discovered to be risk factors for treatment failure. Further prospective cohort and qualitative studies should be conducted to improve the quality of care in paediatric ART clinics to reduce the incidence or burden of first line treatment failure among TB and HIV co-infected children. BioMed Central 2022-03-03 /pmc/articles/PMC8892785/ /pubmed/35241036 http://dx.doi.org/10.1186/s12887-022-03177-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Chanie, Ermias Sisay
Muche, Achenef Asmamaw
Gobeza, Mengistu Berhanu
Alemu, Eshetie Molla
Addis, Wondimnew Desalegn
Azanaw, Melkalem Mamuye
Gebremariam, Alemayehu Digssie
Tesfa, Desalegn
Engidaw, Melaku Tadege
Atikilit, Getaneh
AbebawTiruneh, Sofonyas
Arage, Getachew
Half-life time prediction of developing first-line antiretroviral treatment failure and its risk factors among TB and HIV co-infected children in Northwest Ethiopia; multi setting historical follow-up study
title Half-life time prediction of developing first-line antiretroviral treatment failure and its risk factors among TB and HIV co-infected children in Northwest Ethiopia; multi setting historical follow-up study
title_full Half-life time prediction of developing first-line antiretroviral treatment failure and its risk factors among TB and HIV co-infected children in Northwest Ethiopia; multi setting historical follow-up study
title_fullStr Half-life time prediction of developing first-line antiretroviral treatment failure and its risk factors among TB and HIV co-infected children in Northwest Ethiopia; multi setting historical follow-up study
title_full_unstemmed Half-life time prediction of developing first-line antiretroviral treatment failure and its risk factors among TB and HIV co-infected children in Northwest Ethiopia; multi setting historical follow-up study
title_short Half-life time prediction of developing first-line antiretroviral treatment failure and its risk factors among TB and HIV co-infected children in Northwest Ethiopia; multi setting historical follow-up study
title_sort half-life time prediction of developing first-line antiretroviral treatment failure and its risk factors among tb and hiv co-infected children in northwest ethiopia; multi setting historical follow-up study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8892785/
https://www.ncbi.nlm.nih.gov/pubmed/35241036
http://dx.doi.org/10.1186/s12887-022-03177-6
work_keys_str_mv AT chanieermiassisay halflifetimepredictionofdevelopingfirstlineantiretroviraltreatmentfailureanditsriskfactorsamongtbandhivcoinfectedchildreninnorthwestethiopiamultisettinghistoricalfollowupstudy
AT mucheachenefasmamaw halflifetimepredictionofdevelopingfirstlineantiretroviraltreatmentfailureanditsriskfactorsamongtbandhivcoinfectedchildreninnorthwestethiopiamultisettinghistoricalfollowupstudy
AT gobezamengistuberhanu halflifetimepredictionofdevelopingfirstlineantiretroviraltreatmentfailureanditsriskfactorsamongtbandhivcoinfectedchildreninnorthwestethiopiamultisettinghistoricalfollowupstudy
AT alemueshetiemolla halflifetimepredictionofdevelopingfirstlineantiretroviraltreatmentfailureanditsriskfactorsamongtbandhivcoinfectedchildreninnorthwestethiopiamultisettinghistoricalfollowupstudy
AT addiswondimnewdesalegn halflifetimepredictionofdevelopingfirstlineantiretroviraltreatmentfailureanditsriskfactorsamongtbandhivcoinfectedchildreninnorthwestethiopiamultisettinghistoricalfollowupstudy
AT azanawmelkalemmamuye halflifetimepredictionofdevelopingfirstlineantiretroviraltreatmentfailureanditsriskfactorsamongtbandhivcoinfectedchildreninnorthwestethiopiamultisettinghistoricalfollowupstudy
AT gebremariamalemayehudigssie halflifetimepredictionofdevelopingfirstlineantiretroviraltreatmentfailureanditsriskfactorsamongtbandhivcoinfectedchildreninnorthwestethiopiamultisettinghistoricalfollowupstudy
AT tesfadesalegn halflifetimepredictionofdevelopingfirstlineantiretroviraltreatmentfailureanditsriskfactorsamongtbandhivcoinfectedchildreninnorthwestethiopiamultisettinghistoricalfollowupstudy
AT engidawmelakutadege halflifetimepredictionofdevelopingfirstlineantiretroviraltreatmentfailureanditsriskfactorsamongtbandhivcoinfectedchildreninnorthwestethiopiamultisettinghistoricalfollowupstudy
AT atikilitgetaneh halflifetimepredictionofdevelopingfirstlineantiretroviraltreatmentfailureanditsriskfactorsamongtbandhivcoinfectedchildreninnorthwestethiopiamultisettinghistoricalfollowupstudy
AT abebawtirunehsofonyas halflifetimepredictionofdevelopingfirstlineantiretroviraltreatmentfailureanditsriskfactorsamongtbandhivcoinfectedchildreninnorthwestethiopiamultisettinghistoricalfollowupstudy
AT aragegetachew halflifetimepredictionofdevelopingfirstlineantiretroviraltreatmentfailureanditsriskfactorsamongtbandhivcoinfectedchildreninnorthwestethiopiamultisettinghistoricalfollowupstudy